A Phase 3 interventional study of Ranibizumab in Macular Edema, sponsored by Genentech, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-21.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.
Among the 91 studies testing ranibizumab in Macular Edema, this one is the 56th largest by enrollment, is one of 4 that started in 2016, is one of 25 in phase 3, and was the 76th registered.
758 studies on the registry are indexed under Macular Edema; 66 are open to participants now.
Browse Macular Edema studies →None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 44 Macular Edema studies recruiting now, 31 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 28 · Phase 3 28 · Phase 4 26
First in 2004; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 50 across the 91 interventional studies. Of the 65 that completed or were terminated, 39 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 91 have an industry lead sponsor. The 10 most frequent:
This study is registered under Genentech, Inc., one of the names counted as Hoffmann-La Roche. Under that name alone:
Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2016, is one of 14 in phase 3, and was the 8th registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
None of the studies under way reaches primary completion within a year.
Among the 91 studies testing ranibizumab in Macular Edema, from their registry updates:
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter study designed to evaluate usability of ranibizumab PFS in patients with neovascular age related macular degeneration or macular edema secondary to retinal vein occlusion.
The purpose of this study is to assess the ability of HCPs to follow the instructions for use (IFU) to prepare and administer a ranibizumab PFS ITV injection dose to patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ocular
Exclusion Criteria:
Concurrent Ocular Conditions
Prior Ocular Therapies
General
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthcare professionals (HCPs) will administer ITV injections of ranibizumab 0.5 mg delivered via PFS to enrolled patients (1 injection to each patient) on Day 1.
Drug: Ranibizumab
Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
Also known as: Lucentis
Percentage of Successful Task Completions
Product use tasks included sequence of steps starting from opening the carton, removing contents from carton to disposing of used PFS and needle. Tasks were considered to be successfully completed if the correct results were achieved without a use error, even if the instructions for use (IFU) were not followed exactly (example: not removing the needle cap prior to adjusting a dose). Usage error was defined as user action or lack of user action while using the medical device that led to a different result than intended by the manufacturer or expected by the user. The ability of HCPs to follow the IFU to prepare and administer a ranibizumab PFS ITV injection dose to patients was evaluated by successful task completion.
Time frame: Day 1
Percentage of PFS Usage Errors on Safety Critical Tasks
Usage error was defined as user action or lack of user action while using the medical device that led to a different result than intended by the manufacturer or expected by the user. Safety critical tasks where those in which use error could have a reasonably foreseeable potential for clinical impact or harm.
Time frame: Day 1
Percentage of PFS Usage Errors on Essential Tasks
Usage error was defined as user action or lack of user action while using the medical device that led to a different result than intended by the manufacturer or expected by the user. Essential tasks were those that were required in order to complete the use process for effective use of the product.
Time frame: Day 1
| Milestone | Ranibizumab PFS - Patients | Ranibizumab PFS - HCPs |
|---|---|---|
| Started | 35 | 3 |
| Completed | 35 | 3 |
| Not completed | 0 | 0 |
Product use tasks included sequence of steps starting from opening the carton, removing contents from carton to disposing of used PFS and needle. Tasks were considered to be successfully completed if the correct results were achieved without a use error, even if the instructions for use (IFU) were not followed exactly (example: not removing the needle cap prior to adjusting a dose). Usage error was defined as user action or lack of user action while using the medical device that led to a different result than intended by the manufacturer or expected by the user. The ability of HCPs to follow the IFU to prepare and administer a ranibizumab PFS ITV injection dose to patients was evaluated by successful task completion.
| percentage of tasks | Ranibizumab PFS |
|---|---|
| Open the carton | 100 |
| Remove contents from carton | 100 |
| Peel the lid off the blister pack | 100 |
| Carefully remove the PFS using aseptic technique | 100 |
| Snap off PFS cap | 100 |
| Firmly screw needle onto the Luer lock of PFS | 100 |
| Remove needle cap | 100 |
| Dose preparation: aligning stopper with dose line | 100 |
| Insert PFS at injection site | 100 |
| Slowly inject full dose | 100 |
| Remove PFS from injection site | 100 |
| Dispose of used PFS and needle | 100 |
Usage error was defined as user action or lack of user action while using the medical device that led to a different result than intended by the manufacturer or expected by the user. Safety critical tasks where those in which use error could have a reasonably foreseeable potential for clinical impact or harm.
| percentage of usage errors | Ranibizumab PFS |
|---|---|
| Percentage of PFS Usage Errors on Safety Critical Tasks | 0 |
Usage error was defined as user action or lack of user action while using the medical device that led to a different result than intended by the manufacturer or expected by the user. Essential tasks were those that were required in order to complete the use process for effective use of the product.
| percentage of usage errors | Ranibizumab PFS |
|---|---|
| Percentage of PFS Usage Errors on Essential Tasks | 0 |
Collected over Day 1 to Day 7. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab PFS | — | 0/35 (0%) | 1/35 (2.9%) |
| Event | Ranibizumab PFS |
|---|---|
| Conjunctival hemorrhageEye disorders | 1/35 |
All enrolled patients.
| Age, Continuous(years) | Ranibizumab PFS |
|---|---|
| Mean | 78.3 ± 6.8 |
| Sex/Gender, Customized(patients) | Ranibizumab PFS |
|---|---|
| Female | 0 |
| Male | 0 |
| Unknown | 35 |
Ran from Mar 2016 to primary completion in Apr 2016, 0 months.
Results were first posted in Jul 2017, 1 year 3 months after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 0 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab